[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579257":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":60,"locations":66,"responsibleParty":93,"collaborators":11,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":11,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":11,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Gradual titration group","EXPERIMENTAL",null,[13,14,15,16,17,18],"Drug: BR5402A","Drug: BR5402B","Drug: BR5402C","Drug: BR5402C-1","Drug: BR5402D","Drug: BR5402D-1",{"label":20,"type":21,"description":11,"interventionNames":22},"Conventional titration group","ACTIVE_COMPARATOR",[23,24,15,16,17],"Drug: BR5402A-1","Drug: BR5402B-1",[26,31,36,39,44,47,52,55],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","BR5402A","Subjects take the investigational products once a day",[9],{"type":27,"name":32,"description":29,"armGroupLabels":33,"otherNames":34},"BR5402A-1",[20],[35],"Placebo of BR5402A",{"type":27,"name":37,"description":29,"armGroupLabels":38,"otherNames":11},"BR5402B",[9],{"type":27,"name":40,"description":29,"armGroupLabels":41,"otherNames":42},"BR5402B-1",[20],[43],"Placebo of BR5402B",{"type":27,"name":45,"description":29,"armGroupLabels":46,"otherNames":11},"BR5402C",[20,9],{"type":27,"name":48,"description":29,"armGroupLabels":49,"otherNames":50},"BR5402C-1",[20,9],[51],"Placebo of BR5402C",{"type":27,"name":53,"description":29,"armGroupLabels":54,"otherNames":11},"BR5402D",[20,9],{"type":27,"name":56,"description":29,"armGroupLabels":57,"otherNames":58},"BR5402D-1",[9],[59],"Placebo of BR5402D",[61],{"name":62,"role":63,"phone":64,"phoneExt":11,"email":65},"Shin-young Oh","CONTACT","+82+2-708-8000","syoh@boryung.co.kr",[67,81],{"facility":68,"status":69,"city":70,"state":11,"zip":11,"country":71,"countryCode":11,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Kyungbook National university hospital","RECRUITING","Daegu","South Korea",{"type":73,"coordinates":74},"Point",[75,76],128.59111,35.87028,{"lat":76,"lon":75},[79],{"name":80,"role":63,"phone":11,"phoneExt":11,"email":11},"Seung-hee Won",{"facility":82,"status":83,"city":84,"state":11,"zip":11,"country":71,"countryCode":11,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Hanyang University Guri Hospital","NOT_YET_RECRUITING","Guri-si",{"type":73,"coordinates":86},[87,88],127.1394,37.5986,{"lat":88,"lon":87},[91],{"name":92,"role":63,"phone":11,"phoneExt":11,"email":11},"JoonHo Choi",{"type":94,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100579257","phase-2-a-clinical-trial-to-evaluate-the-safety-and-efficacy-of-olanzapine-titration-schedule-in-patients-with-schizophrenia-100579257",false,"NCT06821945","A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia","A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia","Inclusion Criteria:\n\n* Of patients with schizophrenia in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria, who are judged that administration of low dose is more appropriate than initial recommended dose or standard titration dose of olanzapine to consider medical conditions by investigator\n* Patients with the duration of schizophrenia for more than 1 year at screening visit(Visit 1)\n\nExclusion Criteria:\n\n* Patients diagnosed schizophrenia spectrum and other psychotic disorder(e.g. schizoaffective disorder, etc.), bipolar disorder, depressive disorder, etc., in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria at screening visit(Visit 1)\n* Patients with a history of hospitalization for worsening schizophrenia within 12 weeks at screening visit(Visit 1)","ALL","19 Years",{"count":105,"type":106},120,"ESTIMATED","INTERVENTIONAL",[109],"PHASE2","The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia",[112],"Schizophrenia","2025-09-11",{"date":115,"type":116},"2025-09-15","ACTUAL",{"date":118,"type":116},"2025-05-30",{"date":120,"type":106},"2027-05",{"name":5,"class":6},2]